Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children.
Long-lasting cutaneous warts are a therapeutic challenge, especially widespread or symptomatic recalcitrant warts in children. It can be speculated that natural immunity to these human papillomavirus (HPV)- induced lesions is extremely poor. Therefore ideally treatment should focus on increasing local immune response. Recently imiquimod, a topical immune modifier, has been successfully used in the treatment of external genital warts. Our purpose is to report on our experiences with imiquimod 5% cream applied to therapy-resistant, long-lasting (duration 2-7 years) common warts in children. In 18 children, imiquimod cream was self-applied by the patients or by their parents to the warts twice a day. Assessment for response and occurrence of adverse effects was performed every 4 weeks until clinical cure. Follow-ups could be arranged in 14 of the 18 patients 1-2 years after total clearance. Sixteen of 18 patients experienced total clearance of their warts; 2 showed partial improvement but were lost to follow-up. The mean duration of treatment was 5.8 months. Two of the 14 patients in whom a follow-up was performed showed a small number of new warts after a period of at least 1 year without recurrence. Our data demonstrate that the topical application of imiquimod 5% cream is an effective treatment for long-lasting cutaneous warts in children.
Grussendorf-Conen
E-I
EI
Department of Dermatology, University Hospital RWTH Aachen, Aachen, Germany. elke.grussendorfconen@post.rwth-aachen.de
Jacobs
S
S
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000287:Administration, Topical; D000293:Adolescent; D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D000077271:Imiquimod; D008297:Male; D009824:Ointments; D016896:Treatment Outcome; D014860:Warts / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D009824:Ointments; D000077271:Imiquimod